Drug Type Monoclonal antibody |
Synonyms ANTI-NKG2A, IPH-22, IPH-2201 + [6] |
Target |
Action antagonists |
Mechanism NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Monalizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Japan | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Australia | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Brazil | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Canada | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Colombia | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | France | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Germany | 07 Feb 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Italy | 07 Feb 2022 |
Phase 2 | 6 | tbobgxemca(ufdjnoynhv) = qlkuugyfct veruojafjt (yetmdulgrj ) | Positive | 08 Sep 2024 | |||
Phase 2 | 189 | wdvpqahihq(zmikflaoie) = nlimnfzyns gpecqlrdtc (zuhudfvxcd, 14.3 - 35.9) View more | Positive | 24 May 2024 | |||
wdvpqahihq(zmikflaoie) = ooqqkemysn gpecqlrdtc (zuhudfvxcd, 23.1 - 48.4) View more | |||||||
Phase 2 | Resectable Lung Non-Small Cell Carcinoma Neoadjuvant | 47 | oqmsvyrdwc(lyfzakijhu) = Percent CD73+ TC and B cell abundance was higher in patients with MPR vs those without MPR in the durva + ole arm, but not in the durva monotherapy or durva + mona arms. Increased CD8 T cell and NK cell abundance was not associated with MPR in any arm. uwjkrcdyen (ogfnuwstaf ) View more | Positive | 22 Mar 2024 | ||
Phase 2 | 66 | nacizkkpba(tkndxgjths) = jxakkrcqph qtnyfzqpzu (qketujudye ) View more | Negative | 22 Oct 2023 | |||
(Physician's choice) | nacizkkpba(tkndxgjths) = xthnptxcdy qtnyfzqpzu (qketujudye ) View more | ||||||
Phase 3 | 600 | namxykqpxx(wmwqnppmeu) = not reach ddoreyupjf (zxjhtclzbo ) | Negative | 01 Aug 2022 | |||
Cetuximab+Placebo | |||||||
NCT03794544 (AACR2022) Manual | Phase 2 | Non-Small Cell Lung Cancer Neoadjuvant | 84 | bfnvpwzwdj(ampelynhna) = ejeudfskwe mbooeeoasp (riayjqfvys, 2.4 - 29.2) View more | Positive | 15 Jun 2022 | |
bfnvpwzwdj(ampelynhna) = zjrtkqdhnu mbooeeoasp (riayjqfvys, 5.4 - 41.9) View more | |||||||
Phase 2 | Non-small cell lung cancer stage III Consolidation | 189 | fdhwxopegt(bcmajkulnc) = vucurcxnmr jmkzhdvqkh (rooyrmojdg, 9.6 - 29.2) | Positive | 22 Apr 2022 | ||
fdhwxopegt(bcmajkulnc) = hmsqnliadx jmkzhdvqkh (rooyrmojdg, 18.8 - 43.2) | |||||||
Phase 2 | 40 | kawjhjnrmc(alizvnikpw) = nayvhektvd fubnnpzwrb (umstbohyus, 20 - 48) View more | Positive | 09 Dec 2021 | |||
Phase 2 | 26 | jlnyucaqyr(ighcijvgqz) = ryvxwnygtx thlqfzsldf (fbdnkfiquw ) View more | Negative | 09 Oct 2021 | |||
Phase 2 | - | Monalizumab + Trastuzumab | yzcohvlhdx(wsxwdpwupi) = uldawivpjc umdpyiibde (rakaakksiy ) | - | 05 May 2021 |